• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinicopathological Characteristics of Plurihormonal Pituitary Adenoma.多激素垂体腺瘤的临床病理特征
Front Surg. 2022 Feb 25;9:826720. doi: 10.3389/fsurg.2022.826720. eCollection 2022.
2
Plurihormonal cells of normal anterior pituitary: Facts and conclusions.正常垂体前叶的多激素细胞:事实与结论。
Oncotarget. 2017 Apr 25;8(17):29282-29299. doi: 10.18632/oncotarget.16502.
3
Clinical and morphological characteristics, diagnostic criteria, and outcomes of surgical treatment of TSH-secreting pituitary adenomas.促甲状腺激素分泌型垂体腺瘤的临床与形态学特征、诊断标准及外科治疗结果
Zh Vopr Neirokhir Im N N Burdenko. 2016;80(6):24-35. doi: 10.17116/neiro201680624-35.
4
Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy.MEN1中垂体腺瘤导致的促肾上腺皮质激素(ACTH)和催乳素(PRL)分泌过多,通过药物治疗可得到充分控制。
Endocrinol Diabetes Metab Case Rep. 2017 Apr 6;2017. doi: 10.1530/EDM-17-0027. eCollection 2017.
5
Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma.多激素垂体腺瘤的发病机制、临床特征及治疗
Front Neurosci. 2024 Jan 8;17:1323883. doi: 10.3389/fnins.2023.1323883. eCollection 2023.
6
Secretion of LH, FSH, and PRL shown by cell culture and immunocytochemistry of human functionless pituitary adenomas.通过人无功能垂体腺瘤的细胞培养和免疫细胞化学显示促黄体生成素、促卵泡生成素和催乳素的分泌。
Clin Endocrinol (Oxf). 1981 Aug;15(2):103-12. doi: 10.1111/j.1365-2265.1981.tb00643.x.
7
A case of pituitary somatotroph adenoma with concomitant secretion of growth hormone, prolactin, and adrenocorticotropic hormone--an adenoma derived from primordial stem cell, studied by immunohistochemistry, in situ hybridization, and cell culture.一例同时分泌生长激素、催乳素和促肾上腺皮质激素的垂体生长激素腺瘤——通过免疫组织化学、原位杂交和细胞培养研究的源自原始干细胞的腺瘤
Acta Neurochir (Wien). 1996;138(8):1002-7. doi: 10.1007/BF01411291.
8
A plurihormonal TSH-producing pituitary tumor of monoclonal origin in a patient with hypothyroidism.一名甲状腺功能减退患者体内起源于单克隆的产生促甲状腺激素的多激素性垂体瘤。
Horm Res. 2003;59(5):257-61. doi: 10.1159/000070227.
9
Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature.伴有促肾上腺皮质激素(ACTH)和生长激素(GH)分泌的多激素垂体腺瘤:两例报告并文献复习
Acta Neurochir (Wien). 2014 Jan;156(1):141-6. doi: 10.1007/s00701-013-1890-y. Epub 2013 Oct 1.
10
Pleiomorphism plurihormonal Pit-1-positive macroadenoma with central hyperthyroidism: a rare case report and literature review.Pit-1 阳性多激素分泌垂体大腺瘤伴中枢性甲亢:罕见病例报告及文献复习。
BMC Endocr Disord. 2022 Dec 21;22(1):325. doi: 10.1186/s12902-022-01220-2.

引用本文的文献

1
[Clinical case of plurihormonal pituitary adenoma (STH/ACTH/TSH/FSH/LH-secreting), diagnostic pitfalls].[多激素垂体腺瘤(分泌生长激素/促肾上腺皮质激素/促甲状腺激素/促卵泡激素/促黄体生成素)的临床病例,诊断陷阱]
Probl Endokrinol (Mosk). 2024 Sep 15;70(4):24-31. doi: 10.14341/probl13349.
2
Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma.多激素垂体腺瘤的发病机制、临床特征及治疗
Front Neurosci. 2024 Jan 8;17:1323883. doi: 10.3389/fnins.2023.1323883. eCollection 2023.
3
Plurihormonal Pituitary Neuroendocrine Tumors: Clinical Relevance of Immunohistochemical Analysis.多激素垂体神经内分泌肿瘤:免疫组织化学分析的临床相关性
Diagnostics (Basel). 2024 Jan 11;14(2):170. doi: 10.3390/diagnostics14020170.
4
Preoperative Risk Stratification of Increased MIB-1 Labeling Index in Pituitary Adenoma: A Newly Proposed Prognostic Scoring System.垂体腺瘤中MIB-1标记指数升高的术前风险分层:一种新提出的预后评分系统。
J Clin Med. 2022 Dec 1;11(23):7151. doi: 10.3390/jcm11237151.

本文引用的文献

1
[The significance and role of the 2017 World Health Organization classification of tumors of the pituitary gland].[2017年世界卫生组织垂体肿瘤分类的意义与作用]
Zhonghua Yi Xue Za Zhi. 2018 Mar 6;98(9):641-642. doi: 10.3760/cma.j.issn.0376-2491.2018.09.001.
2
Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification.多激素垂体腺瘤:对所有垂体激素进行免疫染色对于正确分类至关重要。
Histopathology. 2001 Sep;39(3):310-9. doi: 10.1046/j.1365-2559.2001.01204.x.
3
A case of pituitary somatotroph adenoma with concomitant secretion of growth hormone, prolactin, and adrenocorticotropic hormone--an adenoma derived from primordial stem cell, studied by immunohistochemistry, in situ hybridization, and cell culture.一例同时分泌生长激素、催乳素和促肾上腺皮质激素的垂体生长激素腺瘤——通过免疫组织化学、原位杂交和细胞培养研究的源自原始干细胞的腺瘤
Acta Neurochir (Wien). 1996;138(8):1002-7. doi: 10.1007/BF01411291.
4
Recurrent plurihormonal bimorphous pituitary adenoma producing growth hormone, thyrotropin, and prolactin.复发性多激素双形态垂体腺瘤,分泌生长激素、促甲状腺激素和催乳素。
Arch Pathol Lab Med. 1994 Jan;118(1):66-70.
5
Secretion of LH, FSH, and PRL shown by cell culture and immunocytochemistry of human functionless pituitary adenomas.通过人无功能垂体腺瘤的细胞培养和免疫细胞化学显示促黄体生成素、促卵泡生成素和催乳素的分泌。
Clin Endocrinol (Oxf). 1981 Aug;15(2):103-12. doi: 10.1111/j.1365-2265.1981.tb00643.x.
6
Gonadotrophin and alpha subunit secretion by human 'functionless' pituitary adenomas in cell culture: long term effects of luteinizing hormone releasing hormone and thyrotrophin releasing hormone.人“无功能”垂体腺瘤在细胞培养中的促性腺激素和α亚基分泌:促黄体生成素释放激素和促甲状腺激素释放激素的长期作用
Clin Endocrinol (Oxf). 1983 Sep;19(3):325-36. doi: 10.1111/j.1365-2265.1983.tb00006.x.
7
Monomorphous plurihormonal adenoma of the human pituitary. A histologic, immunocytologic and ultrastructural study.人垂体单形性多激素腺瘤。一项组织学、免疫细胞学及超微结构研究。
Cancer. 1984 Apr 1;53(7):1538-44. doi: 10.1002/1097-0142(19840401)53:7<1538::aid-cncr2820530720>3.0.co;2-i.
8
Role of cell and explant culture in the diagnosis and characterization of human pituitary tumours.细胞和外植体培养在人类垂体肿瘤诊断和特征描述中的作用。
Neurosurg Rev. 1985;8(3-4):135-40. doi: 10.1007/BF01815438.
9
Plurihormonal pituitary adenomas.多激素垂体腺瘤
Semin Diagn Pathol. 1986 Feb;3(1):69-82.
10
Growth hormone secreting pituitary adenomas are heterogeneous in cell culture and commonly secrete glycoprotein hormone alpha-subunit.分泌生长激素的垂体腺瘤在细胞培养中具有异质性,且通常分泌糖蛋白激素α亚基。
Clin Endocrinol (Oxf). 1986 Aug;25(2):173-9. doi: 10.1111/j.1365-2265.1986.tb01679.x.

多激素垂体腺瘤的临床病理特征

Clinicopathological Characteristics of Plurihormonal Pituitary Adenoma.

作者信息

Shi Ruoyu, Wan Xueyan, Yan Zisheng, Tan Zhoubin, Liu Xiaojin, Lei Ting

机构信息

Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

Front Surg. 2022 Feb 25;9:826720. doi: 10.3389/fsurg.2022.826720. eCollection 2022.

DOI:10.3389/fsurg.2022.826720
PMID:35284477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8913533/
Abstract

BACKGROUND

As the pathogenesis of plurihormonal pituitary adenoma (PPA) is unclear and the diagnostic criteria are inconsistent, clinicians still find it challenging to diagnose. To analyze the relationship between clinical and pathological characteristics in PPA.

METHODS

The clinical data of patients with 70 PPAs admitted during 2008-2010 and 2019-2020 were collected and analyzed. In particular, hormone examination using cell culture supernatant was performed to confirm PPA cases from 2019 to 2020.

RESULTS

PPA accounted for 13% of all pituitary cases recorded in the same period. There were 30 men and 40 women. Fifty-three percent of patients had one endocrine manifestation, and 1% presented with two endocrine symptoms. However, none of the patients had three endocrine manifestations. The level of one and two types of hormones was elevated in 52 (74.3%) and 5 (7.1%) patients, respectively and that of three types of hormones was increased only in one patient. Immunohistochemical staining for PRL + TSH or FSH/LH was most commonly performed ( = 17), followed by that for PRL + GH + ACTH and PRL + GH + TSH or FSH/LH ( = 14) and PRL + ACTH ( = 10). The primary culture results were consistent with the pathological findings in five (41.7%) patients. Moreover, 4 of 12 patients diagnosed with PPA during 2019-2020 tested positive for SOX2.

CONCLUSION

The pathogenesis of PPA remains elusive due to the lack of specific clinical symptoms and endocrine changes. Examination of hormones on tumor culture supernatant is helpful for its diagnosis.

摘要

背景

由于多激素垂体腺瘤(PPA)的发病机制尚不清楚且诊断标准不一致,临床医生在诊断时仍面临挑战。分析PPA临床与病理特征之间的关系。

方法

收集并分析2008 - 2010年及2019 - 2020年收治的70例PPA患者的临床资料。特别是对2019年至2020年的病例,采用细胞培养上清液进行激素检测以确诊PPA。

结果

PPA占同期记录的所有垂体病例的13%。男性30例,女性40例。53%的患者有1种内分泌表现,1%的患者有2种内分泌症状。然而,没有患者有3种内分泌表现。分别有52例(74.3%)和5例(7.1%)患者的1种和2种激素水平升高,仅1例患者的3种激素水平升高。最常进行PRL + TSH或FSH/LH的免疫组化染色(n = 17),其次是PRL + GH + ACTH和PRL + GH + TSH或FSH/LH(n = 14)以及PRL + ACTH(n = 10)。5例(41.7%)患者的原代培养结果与病理结果一致。此外,2019 - 2020年诊断为PPA的12例患者中有4例SOX2检测呈阳性。

结论

由于缺乏特异性临床症状和内分泌变化,PPA的发病机制仍不清楚。检测肿瘤培养上清液中的激素有助于其诊断。